$56.00
Manufacturer: Ukraine
Epilepsy. Adults and children from 13 years old. Additional therapy or monotherapy for partial and generalized epilepsy seizures, including tonic-clonic seizures. Attacks associated with Lennox-Gastaut syndrome. The drug Lamotrin is prescribed as an additional therapy, but in Lennox-Gastaut syndrome, it can be intended as an initial antiepileptic drug (PEP). Children from 2 to 12 years old. Additional therapy for partial and generalized epilepsy seizures, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Monotherapy of typical absence seizures.
Description
Lamotrin-100 №60 Storage
active substance: lamotrigine;
1 tablet contains lamotrigine 25 mg or 50 mg or 100 mg;
Excipients: microcrystalline cellulose, colloidal anhydrous silica, povidone, sodium starch glycolate (type A), lactose monohydrate, magnesium stearate.
Lamotrin-100 №60 Dosage form
Tablets.
main physical and chemical properties: tablets of white or almost white color, round shape, with a biconvex surface, with a line (Lamotrin 50 and Lamotrin 100), without a line (Lamotrin 25).
Lamotrin-100 №60 Pharmacotherapeutic group
Antiepileptic drugs. Lamotrigine. ATX code N03A X09.
Lamotrin-100 №60 Pharmacological properties
Pharmacodynamics
Lamotrigine, a derivative of phenyltriazine, is an antiepileptic drug whose mechanism of action is to block potential-dependent sodium channels of presynaptic membranes of neurons in the slow inactivation phase and inhibit the excessive release of excitatory neurotransmitters, primarily in the development of glumin, primarily glutetransmitters.
Pharmacokinetics
After ingestion, the drug is rapidly and completely absorbed in the digestive tract. The maximum concentration in blood plasma is reached in about 2.5 hours.
Lamotrigine undergoes extensive metabolism, the main metabolite being N-glucuronide.
In adults, the half-life is 29 hours. Lamotrigine has a linear pharmacological profile. In children, the half-life is shorter than in adults. It is excreted mainly as metabolites and partly unchanged, mainly in the urine. In children, the half-life is shorter than in adults.
Indication
Epilepsy.
Adults and children over 13 years of age: monotherapy and adjunctive therapy for partial and generalized epileptic seizures, including tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. The drug Lamotrin is prescribed as adjunctive therapy, but in Lennox-Gastaut syndrome it can be prescribed as an initial antiepileptic drug (PEP).
Children 2 to 12 years of age: adjunctive therapy for epilepsy, including partial and generalized seizures, including tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
Monotherapy of typical absences.
Bipolar disorder in adults.
Adults (from 18 years old).
To prevent depressive states in patients with bipolar I disorder, who mainly suffer from depressive states.
Lamotrigine is not indicated for the immediate treatment of manic or depressive episodes.
Contraindication
Hypersensitivity to lamotrigine or to other components of the drug.
Recent Reviews